Project cooperationUpdated on 2 April 2026
Core Technologies for Precision Medicine
Head of Public Funding at CBmed GmbH
Graz, Austria
About
CBmed provides a comprehensive suite of core technologies enabling applied precision medicine, integrating state‑of‑the‑art wet‑lab capabilities with advanced data science workflows. CBmed’s in‑house precision medicine laboratories cover key immunology and translational research objectives, including flow cytometry (FACS), single‑ and multiplex immunofluorescent tissue imaging, advanced 2D and 3D cell culture systems, ex vivo compound screening, and live‑cell imaging.
All technologies are operated under high‑quality and reproducibility standards and are fully integrated into CBmed’s laboratory information and management system, ensuring standardized documentation, traceability, and robust quality control across projects. Raw biological material, including blood, tissue, and cells, is processed in collaboration with partners from the Medical Science City Graz and a broader clinical and academic network.
CBmed’s wet‑lab platforms are closely linked to an in‑house data science group with expertise in biostatistics, computational biology, data engineering, machine learning, image analysis, and DevOps. This tight integration enables advanced analytical workflows for complex biological and imaging datasets, supporting translational interpretation and downstream clinical relevance.
Organisation
Similar opportunities
Project cooperation
Ex Vivo Compound Screening and Drug Repurposing
- Partner seeks Consortium/Coordinator
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
- DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-04: Towards climate resilient, prepared and carbon neutral populations and healthcare systems
- DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-01: Towards a better understanding and anticipation of the impacts of climate change on health
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
Leen Assil Companioni
Head of Public Funding at CBmed GmbH
Graz, Austria
Project cooperation
Digital Twin–Guided Development of Stem Cell Organoids for Disease Modeling and Tissue Repair
- Consortium/Coordinator seeks Partners
- DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
Ahmed Morsy
Assistant Professor at Konkuk university
Seoul, South Korea
Project cooperation
Research tools and solutions for lipid nanoparticles (LNPs)
Laszlo Puskas
CEO at Anthelos KFT
Szeged, Hungary